LEMAITRE VASCULAR INC (LMAT) Stock Fundamental Analysis
NASDAQ:LMAT - Nasdaq - US5255582018 - Common Stock - Currency: USD
Overall LMAT gets a fundamental rating of 7 out of 10. We evaluated LMAT against 187 industry peers in the Health Care Equipment & Supplies industry. LMAT has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. LMAT is not valued too expensively and it also shows a decent growth rate. These ratings would make LMAT suitable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year LMAT was profitable.
LMAT had a positive operating cash flow in the past year.
In the past 5 years LMAT has always been profitable.
Each year in the past 5 years LMAT had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 8.12%, LMAT belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
Looking at the Return On Equity, with a value of 12.99%, LMAT belongs to the top of the industry, outperforming 89.84% of the companies in the same industry.
With an excellent Return On Invested Capital value of 7.67%, LMAT belongs to the best of the industry, outperforming 86.10% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for LMAT is in line with the industry average of 7.89%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.12% | ||
| ROE | 12.99% | ||
| ROIC | 7.67% |
ROA(3y)7.77%
ROA(5y)8.17%
ROE(3y)10.28%
ROE(5y)10.74%
ROIC(3y)8.26%
ROIC(5y)8.93%
1.3 Margins
LMAT's Profit Margin of 19.96% is amongst the best of the industry. LMAT outperforms 94.65% of its industry peers.
LMAT's Profit Margin has improved in the last couple of years.
With an excellent Operating Margin value of 23.43%, LMAT belongs to the best of the industry, outperforming 94.12% of the companies in the same industry.
LMAT's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 68.80%, LMAT is in the better half of the industry, outperforming 77.54% of the companies in the same industry.
In the last couple of years the Gross Margin of LMAT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 23.43% | ||
| PM (TTM) | 19.96% | ||
| GM | 68.8% |
OM growth 3Y0.27%
OM growth 5Y5.61%
PM growth 3Y4.76%
PM growth 5Y5.57%
GM growth 3Y1.48%
GM growth 5Y0.13%
2. Health
2.1 Basic Checks
LMAT has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
LMAT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LMAT has been increased compared to 5 years ago.
The debt/assets ratio for LMAT is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 7.37 indicates that LMAT is not in any danger for bankruptcy at the moment.
The Altman-Z score of LMAT (7.37) is better than 86.10% of its industry peers.
LMAT has a debt to FCF ratio of 4.09. This is a neutral value as LMAT would need 4.09 years to pay back of all of its debts.
LMAT has a better Debt to FCF ratio (4.09) than 85.56% of its industry peers.
LMAT has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.48, LMAT perfoms like the industry average, outperforming 42.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 4.09 | ||
| Altman-Z | 7.37 |
ROIC/WACC0.87
WACC8.85%
2.3 Liquidity
LMAT has a Current Ratio of 16.49. This indicates that LMAT is financially healthy and has no problem in meeting its short term obligations.
LMAT's Current ratio of 16.49 is amongst the best of the industry. LMAT outperforms 97.86% of its industry peers.
LMAT has a Quick Ratio of 13.83. This indicates that LMAT is financially healthy and has no problem in meeting its short term obligations.
LMAT has a better Quick ratio (13.83) than 95.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 16.49 | ||
| Quick Ratio | 13.83 |
3. Growth
3.1 Past
LMAT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.13%, which is quite impressive.
The Earnings Per Share has been growing by 17.13% on average over the past years. This is quite good.
Looking at the last year, LMAT shows a quite strong growth in Revenue. The Revenue has grown by 13.19% in the last year.
Measured over the past years, LMAT shows a quite strong growth in Revenue. The Revenue has been growing by 13.41% on average per year.
EPS 1Y (TTM)31.13%
EPS 3Y15.47%
EPS 5Y17.13%
EPS Q2Q%9.09%
Revenue 1Y (TTM)13.19%
Revenue growth 3Y12.5%
Revenue growth 5Y13.41%
Sales Q2Q%11.95%
3.2 Future
The Earnings Per Share is expected to grow by 8.65% on average over the next years. This is quite good.
The Revenue is expected to grow by 9.07% on average over the next years. This is quite good.
EPS Next Y13.23%
EPS Next 2Y11.97%
EPS Next 3Y12.28%
EPS Next 5Y8.65%
Revenue Next Year11.52%
Revenue Next 2Y10.16%
Revenue Next 3Y10.14%
Revenue Next 5Y9.07%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 42.27, which means the current valuation is very expensive for LMAT.
Based on the Price/Earnings ratio, LMAT is valued a bit cheaper than the industry average as 70.05% of the companies are valued more expensively.
LMAT is valuated expensively when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 34.41, the valuation of LMAT can be described as expensive.
70.05% of the companies in the same industry are more expensive than LMAT, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 21.76. LMAT is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.27 | ||
| Fwd PE | 34.41 |
4.2 Price Multiples
72.73% of the companies in the same industry are more expensive than LMAT, based on the Enterprise Value to EBITDA ratio.
75.94% of the companies in the same industry are more expensive than LMAT, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 45.98 | ||
| EV/EBITDA | 23.53 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of LMAT may justify a higher PE ratio.
LMAT's earnings are expected to grow with 12.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.2
PEG (5Y)2.47
EPS Next 2Y11.97%
EPS Next 3Y12.28%
5. Dividend
5.1 Amount
With a yearly dividend of 0.93%, LMAT is not a good candidate for dividend investing.
LMAT's Dividend Yield is rather good when compared to the industry average which is at 1.75. LMAT pays more dividend than 93.05% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.35, LMAT's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.93% |
5.2 History
The dividend of LMAT is nicely growing with an annual growth rate of 13.60%!
LMAT has been paying a dividend for at least 10 years, so it has a reliable track record.
LMAT has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)13.6%
Div Incr Years13
Div Non Decr Years13
5.3 Sustainability
LMAT pays out 33.89% of its income as dividend. This is a sustainable payout ratio.
The dividend of LMAT is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP33.89%
EPS Next 2Y11.97%
EPS Next 3Y12.28%
83.685
-2.06 (-2.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners94.92%
Inst Owner Change0%
Ins Owners8.54%
Ins Owner Change-3.07%
Market Cap1.89B
Analysts76.47
Price Target106.59 (27.37%)
Short Float %6.33%
Short Ratio7.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.93% |
Yearly Dividend0.64
Dividend Growth(5Y)13.6%
DP33.89%
Div Incr Years13
Div Non Decr Years13
Ex-Date
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.01%
Min EPS beat(2)-5.52%
Max EPS beat(2)-2.5%
EPS beat(4)2
Avg EPS beat(4)2.64%
Min EPS beat(4)-5.52%
Max EPS beat(4)10.44%
EPS beat(8)6
Avg EPS beat(8)5.59%
EPS beat(12)7
Avg EPS beat(12)-0.64%
EPS beat(16)8
Avg EPS beat(16)-1.01%
Revenue beat(2)1
Avg Revenue beat(2)-0.28%
Min Revenue beat(2)-2.38%
Max Revenue beat(2)1.83%
Revenue beat(4)2
Avg Revenue beat(4)-0.13%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)1.83%
Revenue beat(8)4
Avg Revenue beat(8)-0.14%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)7
Avg Revenue beat(16)-0.34%
PT rev (1m)0%
PT rev (3m)-1.07%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.06%
EPS NY rev (1m)-0.63%
EPS NY rev (3m)-3.73%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.27 | ||
| Fwd PE | 34.41 | ||
| P/S | 8.36 | ||
| P/FCF | 45.98 | ||
| P/OCF | 39.31 | ||
| P/B | 5.44 | ||
| P/tB | 7.65 | ||
| EV/EBITDA | 23.53 |
EPS(TTM)1.98
EY2.37%
EPS(NY)2.43
Fwd EY2.91%
FCF(TTM)1.82
FCFY2.17%
OCF(TTM)2.13
OCFY2.54%
SpS10.02
BVpS15.39
TBVpS10.94
PEG (NY)3.2
PEG (5Y)2.47
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.12% | ||
| ROE | 12.99% | ||
| ROCE | 9.98% | ||
| ROIC | 7.67% | ||
| ROICexc | 17.81% | ||
| ROICexgc | 31.73% | ||
| OM | 23.43% | ||
| PM (TTM) | 19.96% | ||
| GM | 68.8% | ||
| FCFM | 18.17% |
ROA(3y)7.77%
ROA(5y)8.17%
ROE(3y)10.28%
ROE(5y)10.74%
ROIC(3y)8.26%
ROIC(5y)8.93%
ROICexc(3y)14.32%
ROICexc(5y)13.54%
ROICexgc(3y)28.83%
ROICexgc(5y)29.82%
ROCE(3y)10.75%
ROCE(5y)11.62%
ROICexcg growth 3Y-0.4%
ROICexcg growth 5Y7.52%
ROICexc growth 3Y9.22%
ROICexc growth 5Y8.43%
OM growth 3Y0.27%
OM growth 5Y5.61%
PM growth 3Y4.76%
PM growth 5Y5.57%
GM growth 3Y1.48%
GM growth 5Y0.13%
F-Score5
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 4.09 | ||
| Debt/EBITDA | 2.67 | ||
| Cap/Depr | 70.88% | ||
| Cap/Sales | 3.08% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 76.52% | ||
| Profit Quality | 91.04% | ||
| Current Ratio | 16.49 | ||
| Quick Ratio | 13.83 | ||
| Altman-Z | 7.37 |
F-Score5
WACC8.85%
ROIC/WACC0.87
Cap/Depr(3y)60.87%
Cap/Depr(5y)52.43%
Cap/Sales(3y)2.97%
Cap/Sales(5y)2.88%
Profit Quality(3y)96.62%
Profit Quality(5y)110.46%
High Growth Momentum
Growth
EPS 1Y (TTM)31.13%
EPS 3Y15.47%
EPS 5Y17.13%
EPS Q2Q%9.09%
EPS Next Y13.23%
EPS Next 2Y11.97%
EPS Next 3Y12.28%
EPS Next 5Y8.65%
Revenue 1Y (TTM)13.19%
Revenue growth 3Y12.5%
Revenue growth 5Y13.41%
Sales Q2Q%11.95%
Revenue Next Year11.52%
Revenue Next 2Y10.16%
Revenue Next 3Y10.14%
Revenue Next 5Y9.07%
EBIT growth 1Y29.64%
EBIT growth 3Y12.81%
EBIT growth 5Y19.77%
EBIT Next Year37.67%
EBIT Next 3Y21.1%
EBIT Next 5YN/A
FCF growth 1Y126.79%
FCF growth 3Y7.14%
FCF growth 5Y28.96%
OCF growth 1Y109.55%
OCF growth 3Y7.93%
OCF growth 5Y25.49%